CANF R&D Expenses
Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares · R&D Expenses
CANF R&D Expenses
Latest reported$1.73Mperiod ending
CANF Quarterly R&D Expenses ($640.71K → $1.73M)
Quarterly R&D Expenses
High-resolution chart · PNG
CANF r&d expenses history
Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expenses (USD) |
|---|---|
| 1,728,000 | |
| 1,728,000 | |
| 1,829,500 | |
| 1,829,500 | |
| 1,517,000 | |
| 1,517,000 | |
| 1,436,000 | |
| 1,436,000 | |
| 1,442,500 | |
| 1,442,500 | |
| 1,267,000 | |
| 1,299,000 | |
| 1,356,000 | |
| 2,061,000 | |
| 2,454,000 | |
| 2,036,000 | |
| 1,452,000 | |
| 1,821,000 | |
| 3,101,000 | |
| 2,939,000 | |
| 2,507,000 | |
| 1,303,000 | |
| 2,896,000 | |
| 2,001,000 | |
| 3,283,000 | |
| 3,771,000 | |
| 3,960,000 | |
| 3,056,000 | |
| 2,517,000 | |
| 1,443,000 | |
| 2,019,000 | |
| 1,418,000 | |
| 1,325,000 | |
| 1,313,000 | |
| 1,673,851 | |
| 1,063,722 | |
| 1,295,390 | |
| 1,238,643 | |
| 1,963,255 | |
| 1,529,736 | |
| 1,506,696 | |
| 1,078,405 | |
| 1,417,663 | |
| 916,663 | |
| 933,185 | |
| 588,355 | |
| 784,705 | |
| 859,862 | |
| 1,423,447 | |
| 1,092,304 | |
| 1,564,690 | |
| 706,840 | |
| 1,126,906 | |
| 972,181 | |
| 1,168,401 | |
| 704,743 | |
| 639,130 | |
| 1,080,797 | |
| 778,507 | |
| 698,042 | |
| 913,272 | |
| 1,171,898 | |
| 694,393 | |
| 640,710 |